STOCK TITAN

Inotiv Inc - NOTV STOCK NEWS

Welcome to our dedicated news page for Inotiv (Ticker: NOTV), a resource for investors and traders seeking the latest updates and insights on Inotiv.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Inotiv's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Inotiv's position in the market.

Rhea-AI Summary
Inotiv, Inc. (Nasdaq: NOTV) reported a 10.3% increase in revenue to $135.5 million for the first quarter of fiscal 2024. DSA revenue increased by 8.8% to $44.7 million, and RMS revenue increased by 11.1% to $90.8 million. The company plans to focus on sales and marketing as infrastructure projects near completion. The net loss for Q1 FY 2024 was $15.8 million, down from $86.9 million in Q1 FY 2023. Adjusted EBITDA for Q1 FY 2024 was $9.6 million, compared to $(5.5) million in Q1 FY 2023. The DSA backlog was $152.3 million at December 31, 2023, up from $132.1 million at September 30, 2023. The company reaffirms fiscal 2024 revenues are expected to be in the range of $580 to $590 million, and adjusted EBITDA is expected to be in the range of $75 to $80 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.85%
Tags
earnings
-
Rhea-AI Summary
Inotiv, Inc. (NOTV) will release its fiscal 2024 first-quarter financial results on February 7, 2024, after the stock market closes. The company will host a conference call to discuss the results at 4:30 p.m. Eastern Time on the same day. Interested parties can participate by dialing the provided numbers or accessing the live conference call webcast on the company's website. An online replay will also be available for those unable to listen to the live broadcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.22%
Tags
conferences earnings
-
Rhea-AI Summary
Inotiv, Inc. (Nasdaq: NOTV) announced fiscal year 2023 revenue of $572.4 million, up 4.5% from the previous year. The company expects to continue growing its DSA revenues in fiscal 2024 and anticipates achieving expense reductions. The press release also highlights the completion of site optimization projects and expansion activities, along with financial and operational improvements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.84%
Tags
earnings
Rhea-AI Summary
Inotiv, Inc. (Nasdaq: NOTV) announced a partnership with Vanguard Supply Chain Solutions LLC to integrate its North American transportation operations in-house, expecting to achieve key efficiencies and improve its outgoing supply chain. The transition is expected to be complete by early January 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
none
-
Rhea-AI Summary
Inotiv, Inc. (NOTV) to Release Financial Results for Fiscal 2023 Q4 and Full Year on December 11, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
conferences earnings
-
Rhea-AI Summary
Inotiv, Inc. (Nasdaq: NOTV) provides business updates, including operational and investor conference participation details. The company focuses on expanding its range of services, generating revenue growth, and increasing margins through infrastructure expansion, integration, and asset sales. Inotiv aims to improve its ability to recruit and retain talent, produce positive returns for shareholders, and report fiscal 2023 audited results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.48%
Tags
conferences
Rhea-AI Summary
Inotiv (ticker: INOT) attributes 1156% revenue growth to strategic capacity, key integration initiatives, infrastructure optimization, and global footprint right-sizing. Ranked 127 on the Deloitte Technology Fast 500™, Inotiv credits aggressive acquisition strategy, talented team, new services, organic growth, and growing client base for the top line growth over the past five years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.98%
Tags
none
-
Rhea-AI Summary
Inotiv, Inc. will participate in multiple investor conferences in November 2023. The conferences include the Jefferies London Healthcare Conference on November 15 in London, the 14th Annual Craig-Hallum Alpha Select Conference on November 16 in New York, and the 6th Annual Evercore ISI HealthCONx Conference on November 29 in Miami. The webcast presentations will be available for viewing and replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
conferences
-
Rhea-AI Summary
Inotiv completes sale of businesses in Israel, receiving cash of $1.2 million and a note receivable of $2.5 million. Enters into supply and breeding agreements. Right-sizing global footprint and maintaining strong growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
none
Rhea-AI Summary
Inotiv, Inc. to participate in multiple upcoming investor conferences in September 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.46%
Tags
conferences
Inotiv Inc

Nasdaq:NOTV

NOTV Rankings

NOTV Stock Data

282.15M
23.08M
10.78%
19.98%
4.14%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
West Lafayette

About NOTV

*we are a cro and lab instrumentation provider* basi is a drug discovery and development services company with the energy and expertise to help you with your drug development project. we provide world-class research to the global pharmaceutical industry. our services include preclinical toxicology, early in vivo pk, bioanalysis and a full range of pharmaceutical analysis services. basi also manufactures innovative scientific instruments including the culex® automated in vivo sampling system which can collect blood, bile, microdialysates, activity behavior, telemetry data and more from awake, freely-moving subjects. we are known for our scientific expertise, responsiveness to clients, exemplary regulatory record, and helping our clients meet key milestones on time.